tural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nature Communications; Vol 9, 1029 (2018).

[0168] Alexander Otahal, Renate Fuchs, Faisal A. Al-Allaf, Dieter Blaas (2015). Release of *Vesicular stomatitis* Virus Spike Protein G-Pseudotyped Lentivirus from the Host Cell Is Impaired upon Low-Density Lipoprotein Receptor Overexpression. J Virol. 2015 November; 89(22): 11723-6.

[0169] Mireille Guyader, Etsuko Kiyokawa, Laurence Abrami, Priscilla Turelli, and Didier Trono (2002). Role for Human Immunodeficiency Virus Type 1 Membrane Cholesterol in Viral Internalization. J Virol. 2002 October; 76(20): 10356-10364.

[0170] Rodrigues, Ana & Alves, Paula & Coroadinha, Ana. (2011). Production of Retroviral and Lentiviral Gene Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus. 10.5772/18615.

[0171] Otto-Wilhelm Merten; Matthias Schweizer; Parminder Chahal; Amine A Kamen (2014). Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharmaceutical BioProcessing. 2(2):183-203, April 2014.

1-13. (canceled)

14. A method for producing *Vesicular stomatitis* virus G envelope protein (VSV-G) pseudotyped vector particles or virus like particles thereof containing a transgene, the method comprising:

obtaining cells from a packaging cell line that is negative for expression of low density lipoprotein receptor (LDLR);

causing the cells to express VSV-G, gag/pol, and optionally rev; and

causing the cells to express the transgene;

wherein expression of the aforesaid genes in the cells results in production of the vector particles or virus-like particles containing the transgene; then

harvesting from the cells the vector particles or virus-like particles.

15. The method of claim **14**, wherein the packaging cell line is a human cell line.

16. The method of claim **14**, wherein the packaging cell line has been genetically engineered to prevent expression of LDLR on the cell surface.

17. The method of claim **16**, wherein lentivirus autotransduction by the packaging cell line is reduced by at least 50% as a result of being genetically engineered to prevent expression of LDLR on the cell surface.

18. The method of claim **14**, wherein the packaging cell line is selected from human embryonic kidney (HEK) cell line 293, HEK 293T, HEK EBNA, HEK 293F, HEK 293FT, and HEK 293-S.

19. The method of claim **14**, wherein the packaging cell line has been genetically engineered to stably express VSV-G.

20. The method of claim **19**, wherein the packaging cell line has been genetically engineered to stably express at least one additional gene selected from Gag/pol, rev, and the transgene.

21. The method of claim **14**, wherein the cells are caused to express VSV-G, gag/pol, and the transgene by a process that includes introducing into the cells:

a first Ψ-negative expression vector that encodes gag/pol,

a second Ψ-negative expression vector that encodes rev if the vector particles or virus like particles being produced constitute a lentiviral expression vector,

a third Ψ-negative expression vector that encodes VSV-G, and

a Ψ-positive expression vector that contains the transgene.

22. The method of claim **21**, wherein the cells are caused to express VSV-G, gag/pol, and the transgene by a process that includes co-transfecting the cells with:

a first Ψ-negative retroviral expression vector that encodes gag/pol,

a second Ψ-negative expression vector that encodes rev if the vector particles or virus like particles being produced constitute a lentiviral expression vector,

a third Ψ-negative retroviral expression vector that encodes VSV-G, and

a Ψ-positive retroviral expression vector that contains the transgene.

23. The method of claim **14**, wherein the cells are caused to express VSV-G, gag/pol, rev, and the transgene by a process that includes co-transfecting the cells with:

a first Ψ-negative retroviral expression vector that encodes gag/pol/rev,

a second Ψ-negative retroviral expression vector that encodes VSV-G, and

a Ψ-positive retroviral expression vector that contains the transgene.

24. The method of claim **19**, wherein the cells that stably express VSV-G are caused to express gag/pol and the transgene by a process that includes introducing into the cells:

a first Ψ-negative expression vector that encodes gag/pol,

a second Ψ-negative expression vector that encodes rev if the vector particles or virus like particles being produced constitute a lentiviral expression vector,

a Ψ-positive expression vector that contains the transgene.

25. The method of claim **20**, wherein the cells are caused to express gag/pol, rev, and the transgene by a process that includes introducing into the cells:

Ψ-negative expression vector(s) that encode genes selected from gag/pol, rev, and VSV-G that are not constitutively expressed by the packaging cell line; and

a Ψ-positive expression vector contain the transgene.

26. The method of claim **14**, further comprising formulating the harvested vector particles or virus-like particles as a pharmaceutical composition in a pharmaceutically acceptable carrier.

27. A method of treating a subject in need thereof, comprising administering to the subject a pharmaceutical composition produced according to the method of claim **26**.

28. A combination configured for producing vesicular stomatitis virus G envelope protein (VSV-G) pseudotyped vector particles or virus like particles thereof containing a transgene, the combination comprising:

cells from a packaging cell line that is negative for expression of low density lipoprotein receptor (LDLR); along with

retrovirus expression vector(s) that encode one or more genes selected from VSV-G, gag/pol, and rev.